GlassScriptPhysician profile
Margaret E Goodwin
NPI 1992024525
$885.84
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $113 · 2021: $523 · 2022: $47.49 · 2023: $21.87 · 2024: $23.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $119.06 | 2021-2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $104.11 | 2019-2021 | |
| Corium, LLC | $85.83 | 2021-2022 | |
| Kaleo, INC. | $75.51 | 2019-2021 | |
| Pfizer INC. | $67.91 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $66.11 | 2019-2021 | |
| Glaxosmithkline, LLC. | $62.27 | 2021-2023 | Pediarix, Rotarix, Bexsero |
| Tris Pharma INC | $56.10 | 2020-2021 | |
| Adlon Therapeutics L.P. | $55.48 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $49.04 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $31.33 | 2021 | |
| Sanofi Pasteur INC. | $24.31 | 2021-2022 | |
| Aytu Biopharma, INC. | $18.87 | 2019 | |
| Sobi, INC | $16.00 | 2022 | |
| Cranial Technologies, INC | $15.33 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.67 | 2020 | |
| Seqirus USA INC | $14.38 | 2021 | |
| Quidel Corporation | $9.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Goodwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.